D Durect Corp
D
Closed
0
Overview
Share price change
24h
Min
Max
Employees | 13 |
|---|
Recommendations | Neutral |
|---|---|
12 Months Forecast | +30.89% upside |
Market Cap | 51M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Durect Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Durect Corp Forecast
Price Target
By TipRanks
30.89% upside
12 Months Forecast
Average 2.5 USD 30.89%
High 2.5 USD
Low 2.5 USD
Based on 1 Wall Street analysts offering 12 month price targets forDurect Corp - Dist in the last 3 months.
Financials
$
About Durect Corp
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
